Tirzepatide vs Cagrilintide: Research Comparison
A Side-By-Side Research Comparison Of Tirzepatide And Cagrilintide - a dual incretin agonist versus an amylin analog in metabolic research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Tirzepatide | Cagrilintide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Dual GIP/GLP-1 receptor co-agonist (twincretin); synthetic 39-residue peptide with C18 fatty diacid for albumin binding | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) |
| Evidence Tier | Approved Drug | Investigational |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation |
| Molecular Weight | 4813.45 Da | 4409.01 Da |
| Amino Acid Sequence | 39-aa acylated peptide (C20 diacid) | acylated cyclic amylin analog |
| CAS Number | 2023788-19-2 | 1415456-99-3 |
| Half-Life | ~1 week | ~1 week (weekly SC, acylated) |
| Studied For | Type 2 diabetes management, Chronic weight management / obesity, Obstructive sleep apnea in obesity (FDA approved 2024), Non-alcoholic fatty liver disease (NAFLD/MASH) | Obesity / overweight, Type 2 diabetes, Combination with semaglutide (CagriSema), Amylin receptor agonism for satiety |
About Tirzepatide
The approved dual-incretin weight-loss and diabetes drug; compounded versions are not FDA-evaluated.
Read The Full Tirzepatide MonographAbout Cagrilintide
An investigational amylin weight-loss peptide, often paired with semaglutide.
Read The Full Cagrilintide MonographKey Differences
- Evidence tier differs: Tirzepatide is classified as Approved Drug; Cagrilintide is classified as Investigational.
- Reported half-life differs: Tirzepatide at ~1 week versus Cagrilintide at ~1 week (weekly SC, acylated).
- Primary molecular target differs: Tirzepatide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor); dual incretin axis activation; pancreatic insulin secretion and hypothalamic appetite suppression; Cagrilintide acts on Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation.
Continue Researching
Tirzepatide · Cagrilintide · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.